Spotlight On... Smith & Nephew shareholders balk at $3M in exec bonuses; FDA panel to take up heater-cooler cardiac infections; Baxter-backed app to monitor maternal, child health in India launches; and more...

Shareholders of orthopedic implant specialist Smith & Nephew ($SNN) voted by a narrow majority of 53% to oppose the company's 2015 remuneration report. The nonbinding vote won't actually change those management pay packages, but it is a bit of a symbolic protest. The $3 million was distributed amongst the company's top 60 executives. The allocation of the bonuses was in spite of the fact that the company's shareholder return lagged the median of its peer group, which is against company policy. The exception was made reportedly due to changes last year in Smith & Nephew's peer group of 18 companies--three of them were acquired, resulting in unusually sharp share price increases. WSJ article

@FierceMedDev: Duodenal resurfacing startup Fractyl Labs gets CE mark to treat Type 2 diabetes. More | Follow @FierceMedDev

@EmilyWFierce: New York AG sues insurer over restrictive hep C coverage. Report | Follow @EmilyWFierce

@amirahalidrus: MIT researchers create implant to deliver drugs to pancreatic tumors. Story | Follow @amirahalidrus

> The FDA has said it will hold a panel on June 2-3 to address nontuberculous mycobacteria (NTM) infections associated with the use of heater-cooler devices during cardiac surgical procedures. More

> Baxter-backed ($BAX) mobile health app to monitor the health status of underprivileged pregnant women and their children under age two has launched in India. More

> CRO Boston Biomedical Associates announced it worked with startup CardioFocus in its recent successful effort to win an FDA approval for its HeartLight Endoscopic Ablation System for the treatment of patients with paroxysmal atrial fibrillation. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.